Comment

. 2021 Oct;75(4):990-992.

doi: 10.1016/j.jhep.2021.06.024. Epub 2021 Jun 24.

Reply to: "Progressive cholangiopathy in COVID-19 patients: Other possible diagnoses than ketamine-induced cholangiopathy should be considered"

Vincent Mallet¹; Keta-Cov research group

Collaborators, Affiliations

Collaborators

Keta-Cov research group:
Vincent Mallet², Kilian Bock³, Mourad Dellagi⁴, Marion Tano⁵, Virginie Siorat⁵, Nathanaël Beeker⁴, Pascal Paubel⁵, Paul Doumbe Mandengue², Nicolas Dufour⁶, Torsten Voigtländer³, Jean-Damien Ricard⁷, Pierre Isnard⁸, Vincent Frochot⁹, Emmanuel Letavernier⁹, Lucile Moga¹⁰, Amandine Landrieux¹⁰, Pierre-Emmanuel Rautou¹⁰, Nathalie Pons-Kerjean¹¹, Anaïs Vallet-Pichard², Clémence Hollande², Hélène Fontaine², Laurent Chouchana¹², Coralie Gernez⁷, Carole Burger¹³, Anne Scemla¹³, Christian de Tymowski¹⁴, François Depret¹⁴, Emmanuel Dudoignon¹⁴, Lionel Lamhaut¹⁵, Rémi Flicoteau¹⁶, Géraldine Rousseau¹⁷, Jean-Paul Duong Van Huyen⁸, Jean-Michel Correas¹⁸, Heiner Wedemeyer³, Stanislas Pol²

Affiliations

¹ Assistance Publique-Hôpitaux de Paris, Hôpital Cochin, Hepatology Service, Paris, France. Electronic address: vincent.mallet@aphp.fr.
² Université de Paris, AP-HP, AP-HP.Centre, Groupe Hospitalier Cochin Port Royal, DMU Cancérologie et spécialités médico-chirurgicales, Service d'Hépatologie, Paris, France.
³ Dept. of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Carl-Neuberg-Str.1, 30625 Hannover, Germany; German Center for Infection Research (DZIF), Partner Site Hannover-Braunschweig, France.
⁴ Université de Paris, AP-HP, AP-HP.Centre, Groupe Hospitalier Cochin Port Royal, Clinical Research Unit, Paris, France.
⁵ Université de Paris, Institut Droit et Santé, INSERM UMR S 1145, France; AP-HP, Agence Générale des Équipements et Produits de Santé, Paris, France.
⁶ Centre Hospitalier René Dubos, 95300 Pontoise, France.
⁷ Université de Paris, AP-HP, Hôpital Louis Mourier, DMU Esprit, Service de Réanimation Médico-Chirurgicale, Colombes, France.
⁸ Université de Paris, AP-HP, Hôpital Necker Enfants Malades, DMU Imagina, Service d'Anatomo-Pathologie, Paris, France.
⁹ Sorbonne Université, AP-HP, Hôpital Tenon, DMU Biogem, Service de Physiologie, F-75020 Paris, France; INSERM, UMR S 1155, Hôpital Tenon, F-75020 Paris, France.
¹⁰ Université de Paris, AP-HP, Hôpital Beaujon, Service d'Hépatologie, DMU Digest, Centre de Référence des Maladies Vasculaires du Foie, FILFOIE, ERN RARE-LIVER, Centre de recherche sur l'inflammation, Inserm, UMR 1149, Paris, France.
¹¹ AP-HP, Hôpital Beaujon, Service de Pharmacie, DMU Prisme, Paris, France.
¹² Université de Paris, AP-HP, Hôpital Cochin, DMU Prime, Service de Pharmacovigilance, Paris, France.
¹³ Université de Paris, AP-HP, Hôpital Necker Enfants Malades, DMU Carte, Service de Néphrologie et de Transplantation rénale, Paris, France.
¹⁴ Université de Paris, AP-HP, Groupe Hospitalier St-Louis-Lariboisière, DMU Parabol, Département d'Anesthésie Réanimation et Centre de Traitement des Brûlés, Paris, France; INSERM U942, FHU Promice Paris France; INI-CRCT, Nancy, France.
¹⁵ Université de Paris, AP-HP, Hôpital Necker Enfants Malades, Department of Anesthesiology and Critical Care, Paris, France.
¹⁶ Université de Paris, AP-HP, Hôpital Saint Louis, DMU Prisme, Service de Biostatistique et Information Médicale, Paris, France.
¹⁷ Service de Chirurgie Digestive, Hépato-Bilio-Pancréatique et Transplantation Hépatique, Hôpital Pitié-Salpêtrière, DMU SAPERE - APHP Sorbonne Université, France.
¹⁸ Université de Paris, AP-HP, Hôpital Necker Enfants Malades, DMU Imagina, Service de Radiologie, Paris, France.

PMID: 34174378
PMCID: PMC8223115
DOI: 10.1016/j.jhep.2021.06.024

Comment

Reply to: "Progressive cholangiopathy in COVID-19 patients: Other possible diagnoses than ketamine-induced cholangiopathy should be considered"

Vincent Mallet et al. J Hepatol. 2021 Oct.

. 2021 Oct;75(4):990-992.

doi: 10.1016/j.jhep.2021.06.024. Epub 2021 Jun 24.

Authors

Vincent Mallet¹; Keta-Cov research group

Collaborators

Keta-Cov research group:
Vincent Mallet², Kilian Bock³, Mourad Dellagi⁴, Marion Tano⁵, Virginie Siorat⁵, Nathanaël Beeker⁴, Pascal Paubel⁵, Paul Doumbe Mandengue², Nicolas Dufour⁶, Torsten Voigtländer³, Jean-Damien Ricard⁷, Pierre Isnard⁸, Vincent Frochot⁹, Emmanuel Letavernier⁹, Lucile Moga¹⁰, Amandine Landrieux¹⁰, Pierre-Emmanuel Rautou¹⁰, Nathalie Pons-Kerjean¹¹, Anaïs Vallet-Pichard², Clémence Hollande², Hélène Fontaine², Laurent Chouchana¹², Coralie Gernez⁷, Carole Burger¹³, Anne Scemla¹³, Christian de Tymowski¹⁴, François Depret¹⁴, Emmanuel Dudoignon¹⁴, Lionel Lamhaut¹⁵, Rémi Flicoteau¹⁶, Géraldine Rousseau¹⁷, Jean-Paul Duong Van Huyen⁸, Jean-Michel Correas¹⁸, Heiner Wedemeyer³, Stanislas Pol²

Affiliations

¹ Assistance Publique-Hôpitaux de Paris, Hôpital Cochin, Hepatology Service, Paris, France. Electronic address: vincent.mallet@aphp.fr.
² Université de Paris, AP-HP, AP-HP.Centre, Groupe Hospitalier Cochin Port Royal, DMU Cancérologie et spécialités médico-chirurgicales, Service d'Hépatologie, Paris, France.
³ Dept. of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Carl-Neuberg-Str.1, 30625 Hannover, Germany; German Center for Infection Research (DZIF), Partner Site Hannover-Braunschweig, France.
⁴ Université de Paris, AP-HP, AP-HP.Centre, Groupe Hospitalier Cochin Port Royal, Clinical Research Unit, Paris, France.
⁵ Université de Paris, Institut Droit et Santé, INSERM UMR S 1145, France; AP-HP, Agence Générale des Équipements et Produits de Santé, Paris, France.
⁶ Centre Hospitalier René Dubos, 95300 Pontoise, France.
⁷ Université de Paris, AP-HP, Hôpital Louis Mourier, DMU Esprit, Service de Réanimation Médico-Chirurgicale, Colombes, France.
⁸ Université de Paris, AP-HP, Hôpital Necker Enfants Malades, DMU Imagina, Service d'Anatomo-Pathologie, Paris, France.
⁹ Sorbonne Université, AP-HP, Hôpital Tenon, DMU Biogem, Service de Physiologie, F-75020 Paris, France; INSERM, UMR S 1155, Hôpital Tenon, F-75020 Paris, France.
¹⁰ Université de Paris, AP-HP, Hôpital Beaujon, Service d'Hépatologie, DMU Digest, Centre de Référence des Maladies Vasculaires du Foie, FILFOIE, ERN RARE-LIVER, Centre de recherche sur l'inflammation, Inserm, UMR 1149, Paris, France.
¹¹ AP-HP, Hôpital Beaujon, Service de Pharmacie, DMU Prisme, Paris, France.
¹² Université de Paris, AP-HP, Hôpital Cochin, DMU Prime, Service de Pharmacovigilance, Paris, France.
¹³ Université de Paris, AP-HP, Hôpital Necker Enfants Malades, DMU Carte, Service de Néphrologie et de Transplantation rénale, Paris, France.
¹⁴ Université de Paris, AP-HP, Groupe Hospitalier St-Louis-Lariboisière, DMU Parabol, Département d'Anesthésie Réanimation et Centre de Traitement des Brûlés, Paris, France; INSERM U942, FHU Promice Paris France; INI-CRCT, Nancy, France.
¹⁵ Université de Paris, AP-HP, Hôpital Necker Enfants Malades, Department of Anesthesiology and Critical Care, Paris, France.
¹⁶ Université de Paris, AP-HP, Hôpital Saint Louis, DMU Prisme, Service de Biostatistique et Information Médicale, Paris, France.
¹⁷ Service de Chirurgie Digestive, Hépato-Bilio-Pancréatique et Transplantation Hépatique, Hôpital Pitié-Salpêtrière, DMU SAPERE - APHP Sorbonne Université, France.
¹⁸ Université de Paris, AP-HP, Hôpital Necker Enfants Malades, DMU Imagina, Service de Radiologie, Paris, France.

PMID: 34174378
PMCID: PMC8223115
DOI: 10.1016/j.jhep.2021.06.024

No abstract available

Keywords: COVID-19; Chemical and Drug Induced Liver Injury; Cholangiopathy; Cholangitis; Cholestasis; Intrahepatic; Ketamine.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest The authors declare no conflicts of interest that pertain to this work. Please refer to the accompanying ICMJE disclosure forms for further details.

Figures

**Fig. 1**
Distribution of maximum total serum bilirubin level by hospital consumption of ketamine, midazolam, propofol, and first serum C-reactive protein measurement. Data are for COVID-19 patients treated with mechanical ventilation between February 6, 2020 and April 20, 2021 in 15 adult hospitals of the Assistance Publique - Hôpitaux de Paris (AP-HP). Data were extracted from the heath datawarehouses of the AP-HP. Hospital consumption of sedative drugs corresponded to the ratio of total drug consumption to the number of COVID-19 patients who underwent mechanical ventilation in each hospital. (This figure appears in color on the web.)

See this image and copyright information in PMC

Comment on

Progressive cholangiopathy in COVID-19 patients: Other possible diagnoses than ketamine-induced cholangiopathy should be considered.
Deltenre P, Moreno C, Trépo E. Deltenre P, et al. J Hepatol. 2021 Oct;75(4):989-990. doi: 10.1016/j.jhep.2021.02.036. Epub 2021 Mar 19. J Hepatol. 2021. PMID: 33753153 Free PMC article. No abstract available.

References

1. Keta-Cov Research Group Intravenous ketamine and progressive cholangiopathy in COVID-19 patients. J Hepatol. 2021;74(5):1243–1244. - PMC - PubMed
1. Deltenre P., Moreno C., Trépo E. Progressive cholangiopathy in COVID-19 patients: other possible diagnoses than ketamine-induced cholangiopathy should be considered. J Hepatol. 2021;75:989–990. - PMC - PubMed
1. Faruqui S., Okoli F.C., Olsen S.K., Feldman D.M., Kalia H.S., Park J.S., et al. Cholangiopathy after severe COVID-19: clinical features and prognostic implications. Am J Gastroenterol. 2021 doi: 10.14309/ajg.0000000000001264. - DOI - PubMed
1. Knooihuizen S.A.I., Aday A., Lee W.M. Ketamine-Induced sclerosing cholangitis (KISC) in a critically ill patient with COVID-19. Hepatology. 2020 doi: 10.1002/hep.31650. - DOI - PMC - PubMed
1. Bütikofer S., Lenggenhager D., Garcia P.D.W., Maggio E.M., Haberecker M., Reiner C.S., et al. Secondary sclerosing cholangitis as cause of persistent jaundice in patients with severe COVID-19. Liver Int. 2021 doi: 10.1111/liv.14971. - DOI - PMC - PubMed

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions

LinkOut - more resources

Full Text Sources
Medical
- MedlinePlus Health Information

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Reply to: "Progressive cholangiopathy in COVID-19 patients: Other possible diagnoses than ketamine-induced cholangiopathy should be considered"

Collaborators

Affiliations

Reply to: "Progressive cholangiopathy in COVID-19 patients: Other possible diagnoses than ketamine-induced cholangiopathy should be considered"

Authors

Collaborators

Affiliations

Conflict of interest statement

Figures

Comment on

References

Publication types

MeSH terms

Substances

LinkOut - more resources

Full Text Sources

Medical